Filing Flows › Atara Biotherapeutics (ATRA) › Q2 2026 › vs Q1 2026
Atara Biotherapeutics (ATRA) Q2 2026 vs Q1 2026 (quarter over quarter)
Atara Biotherapeutics's revenue rose $114K (+22%) from $516K in Q1 2026 to $630K in Q2 2026.
Atara Biotherapeutics, Q2 2026: revenue $630K (-96% year over year), operating margin -749.2%, net loss $4.8M, operating cash flow −$3.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $630K | $516K | $114K | +22% |
| Net loss | $4.8M | $4.1M | $689K | +17% |
| Costs & expenses | $5.5M | $4.7M | $803K | +17% |
| Operating costs | $5.3M | $3.9M | $1.5M | +38% |
| Interest & other, net | $113K | $776K | −$663K | -85% |
| Income tax | $1K | $0 | $1K | — |
| Research & development | $1.3M | $164K | $1.2M | +720% |
| General & admin | $3.8M | $3.6M | $217K | +6% |
| Other operating costs | $191K | $124K | $67K | +54% |
| Operating cash sources | $4.8M | $4.1M | $689K | +17% |
| Depreciation & amortization | $14K | $29K | −$15K | -52% |
| Share-based compensation | $394K | $749K | −$355K | -47% |
| Working capital & other | $1.1M | $294K | $794K | +270% |
| Cash used in operations | $3.3M | $3.1M | $265K | +9% |
| Net loss absorbed | $4.8M | $4.1M | $689K | +17% |
Questions
How much did Atara Biotherapeutics's revenue grow quarter over quarter in Q2 2026?
Atara Biotherapeutics's revenue rose $114K (+22%) from $516K in Q1 2026 to $630K in Q2 2026.